Abstract

Objective To develop a noninvasive and quick method of distinguishing neuroblastoma and gangliocytoma so as to guide their therapeutics. Methods From May 2010 to December 2013, preoperative serum samples were collected from 47 patients with primary neuroblastoma and 24 patients with primary gangliocytoma. Differential serum proteins were detected by laser desorption ionization time of flight mass spectroscopy proteomic technique. High performance liquid chromatography and two dimensions-liquid chromatography-linear trap quadrupole-mass spectrometer techniques were employed. Results The peak value of differential proteins was 9 569.4 D. And the protein of 9 569.4 D was verified as serum amyloid A2. Conclusions Proteomic technology has identified the differential protein of neuroblastoma and gangliocytoma as amyloid protein A2. And the results shall provide rationales for further clinical applications. Key words: Neuroblastoma; Ganglioneuroma; Serum amyloid A protein

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.